TScan Therapeutics, Inc. SEC filings TCRX
TScan Therapeutics, Inc. has 334 filings in SEC EDGAR's recent list, going back to Jul 26, 2019. Its latest annual report, Form ARS, was filed on Apr 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 16, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Mar 4, 2026 | — |
| S-8 | Employee stock plan registration | Mar 5, 2025 | — |
| S-3 | Shelf registration | Mar 5, 2025 | — |
| 424B5 | Prospectus supplement | Dec 26, 2024 | — |
| S-8 | Employee stock plan registration | Jun 14, 2024 | — |
| 424B5 | Prospectus supplement | Apr 18, 2024 | — |
| FWP | Free writing prospectus | Apr 17, 2024 | — |
| 424B5 | Prospectus supplement | Apr 16, 2024 | — |
| S-3 | Shelf registration | Mar 6, 2024 | — |
| S-8 | Employee stock plan registration | Mar 6, 2024 | — |
| S-8 | Employee stock plan registration | Jun 16, 2023 | — |
| 424B5 | Prospectus supplement | May 30, 2023 | — |
| FWP | Free writing prospectus | May 26, 2023 | — |
| 424B5 | Prospectus supplement | May 25, 2023 | — |
| 424B5 | Prospectus supplement | May 16, 2023 | — |
| S-3/A | Filing | May 16, 2023 | — |
| S-3/A | Filing | May 16, 2023 | — |
| S-3/A | Filing | May 16, 2023 | — |
| S-8 | Employee stock plan registration | Mar 8, 2023 | — |
| S-3 | Shelf registration | Nov 9, 2022 | — |
| S-3 | Shelf registration | Nov 9, 2022 | — |
| S-8 | Employee stock plan registration | Mar 9, 2022 | — |
| 424B4 | Prospectus | Jul 19, 2021 | — |
| S-8 | Employee stock plan registration | Jul 16, 2021 | — |
| FWP | Free writing prospectus | Jul 16, 2021 | — |
| S-1MEF | Filing | Jul 15, 2021 | — |
| S-1/A | Amended registration statement | Jul 12, 2021 | — |
| S-1/A | Amended registration statement | May 14, 2021 | — |
| S-1/A | Amended registration statement | May 5, 2021 | — |
| S-1/A | Amended registration statement | Apr 30, 2021 | — |
| S-1 | Registration statement | Apr 23, 2021 | — |
Showing 31 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TCRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1783328
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.